MiR-506: a Regulator of Chemo-sensitivity Through Suppression of the RAD51-homologous Recombination Axis

Overview

Journal Chin J Cancer

Publisher Biomed Central

Specialty Oncology

Date 2015 Sep 16

PMID 26369335

Citations 18

Authors

Guoyan Liu

Fengxia Xue

Wei Zhang

Affiliations

Soon will be listed here.

Abstract

Ovarian carcinoma is the most lethal gynecologic malignancy. Resistance to platinum is considered the major problem affecting prognosis. Our recent study established that microRNA-506 (miR-506) expression was closely associated with progression-free survival and overall survival in two independent patient cohorts totaling 598 epithelial ovarian cancer cases. Further functional study demonstrated that miR-506 could augment the response to cisplatin and olaparib through targeting RAD51 and suppressing homologous recombination in a panel of ovarian cancer cell lines. Systemic delivery of miR-506 in an orthotopic ovarian cancer mouse model significantly augmented the cisplatin response, thus recapitulating the clinical observation. Therefore, miR-506 plays a functionally important role in homologous recombination and has important therapeutic value for sensitizing cancer cells to chemotherapy, especially in chemo-resistant patients with attenuated expression of miR-506.

Citing Articles

MicroRNA-506 as a tumor suppressor in anaplastic thyroid carcinoma by regulation of WNT and NOTCH signaling pathways.

Navaei Z, Taghehchian N, Zangouei A, Abbaszadegan M, Moghbeli M Iran J Basic Med Sci. 2023; 26(5):594-602.

PMID: 37051101 PMC: 10083834. DOI: 10.22038/IJBMS.2023.69174.15069.

Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.

Havasi A, Cainap S, Havasi A, Cainap C Medicina (Kaunas). 2023; 59(3).

PMID: 36984544 PMC: 10057458. DOI: 10.3390/medicina59030544.

Expression and Prognostic Value of in Adenocarcinoma at the Gastroesophageal Junction.

ReDati D, Yang X, Lei C, Liu L, Ge L, Wang H Iran J Public Health. 2022; 51(10):2231-2243.

PMID: 36415794 PMC: 9647605. DOI: 10.18502/ijph.v51i10.10981.

Identification of new RAD51D-regulating microRNAs that also emerge as potent inhibitors of the Fanconi anemia/homologous recombination pathways.

Hater N, Iwaniuk K, Leifeld C, Gruten P, Wiek C, Raba K Hum Mol Genet. 2022; 31(24):4241-4254.

PMID: 35904444 PMC: 9759333. DOI: 10.1093/hmg/ddac177.

Oncogenic microRNA-181d binding to OGT contributes to resistance of ovarian cancer cells to cisplatin.

Huang W, Chen L, Zhu K, Wang D Cell Death Discov. 2021; 7(1):379.

PMID: 34876558 PMC: 8651739. DOI: 10.1038/s41420-021-00715-6.

References

Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y . Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med. 2005; 7(8):1044-52. DOI: 10.1002/jgm.753. View

Liu G, Yang D, Rupaimoole R, Pecot C, Sun Y, Mangala L . Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst. 2015; 107(7). PMC: 4554255. DOI: 10.1093/jnci/djv108. View

Baumann P, West S . Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci. 1998; 23(7):247-51. DOI: 10.1016/s0968-0004(98)01232-8. View

Tsai M, Kuo Y, Chiu Y, Su Y, Lin Y . Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells. J Pharmacol Exp Ther. 2010; 335(3):830-40. DOI: 10.1124/jpet.110.173146. View

Chen A . PARP inhibitors: its role in treatment of cancer. Chin J Cancer. 2011; 30(7):463-71. PMC: 4013421. DOI: 10.5732/cjc.011.10111. View

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood A . Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011; 306(14):1557-65. PMC: 4159096. DOI: 10.1001/jama.2011.1456. View

Quiros S, Roos W, Kaina B . Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS One. 2011; 6(11):e27183. PMC: 3206939. DOI: 10.1371/journal.pone.0027183. View

Roy R, Chun J, Powell S . BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2011; 12(1):68-78. PMC: 4972490. DOI: 10.1038/nrc3181. View

10.

Bolton K, Chenevix-Trench G, Goh C, Sadetzki S, Ramus S, Karlan B . Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012; 307(4):382-90. PMC: 3727895. DOI: 10.1001/jama.2012.20. View

11.

Yang Z, Waldman A, Wyatt M . Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics. Biochem Pharmacol. 2012; 83(6):741-6. PMC: 3278513. DOI: 10.1016/j.bcp.2011.12.022. View

12.

Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood A . Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics. 2012; 13(13):1523-35. PMC: 3603383. DOI: 10.2217/pgs.12.137. View

13.

Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot C . Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013; 23(2):186-99. PMC: 3603369. DOI: 10.1016/j.ccr.2012.12.020. View

14.

Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D . MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol. 2014; 233(3):308-18. PMC: 4144705. DOI: 10.1002/path.4348. View

15.

Sun Y, Guo F, Bagnoli M, Xue F, Sun B, Shmulevich I . Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer. Chin J Cancer. 2015; 34(1):28-40. PMC: 4302087. DOI: 10.5732/cjc.014.10284. View

16.

Devouassoux-Shisheboran M, Genestie C . Pathobiology of ovarian carcinomas. Chin J Cancer. 2015; 34(1):50-5. PMC: 4302089. DOI: 10.5732/cjc.014.10273. View

17.

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

18.

Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-21. DOI: 10.1038/nature03445. View